



MicroRNAs, epigenetics and disease

Silahtaroglu, Asli; Stenvang, Jan

Published in:
Essays in Biochemistry

DOI:
[10.1042/bse0480165](https://doi.org/10.1042/bse0480165)

Publication date:
2010

Document version
Early version, also known as pre-print

Citation for published version (APA):
Silahtaroglu, A., & Stenvang, J. (2010). MicroRNAs, epigenetics and disease. *Essays in Biochemistry*, 48(1), 165-185. <https://doi.org/10.1042/bse0480165>

MicroRNAs, epigenetics and disease

Asli Silahtaroglu*¹ and Jan Stenvang†

**Wilhelm Johannsen Centre for Functional Genome Research, Department of Cellular and Molecular Medicine, University of Copenhagen, Blegdamsvej 3, DK-2200, Copenhagen N, Denmark, and †Department of Veterinary Disease Biology, Faculty of Life Sciences (LIFE), University of Copenhagen, Dyrlægevej 88, 1870 Frederiksberg C, Denmark*

Abstract

Epigenetics is defined as the heritable changes that affect gene expression without changing the DNA sequence. Epigenetic regulation of gene expression can be through different mechanisms such as DNA methylation, histone modifications and nucleosome positioning. MicroRNAs are short RNA molecules which do not code for a protein but have a role in post-transcriptional silencing of multiple target genes by binding to their 3' UTRs (untranslated regions). Both epigenetic mechanisms, such as DNA methylation and histone modifications, and the microRNAs are crucial for normal differentiation, development and maintenance of tissue-specific gene expression. These mechanisms also explain how cells with the same DNA content can differentiate into cells with different functions. Changes in epigenetic processes can lead to changes in gene function, cancer formation and progression, as well as other diseases. In the present chapter we will mainly focus on microRNAs and methylation and their implications in human disease, mainly in cancer.

¹To whom correspondence should be addressed (email asli@sund.ku.dk).

Introduction to microRNAs

miRNAs (microRNAs) are a class of short (approx. 22 nt) endogenous non-coding RNAs that act as post-transcriptional regulators of gene expression. According to the September 2009 release of the microRNA database mirbase (<http://www.mirbase.org/>) there are 10883 miRNA entries from vertebrates, insects, plants and viruses discovered either by cloning or bioinformatics [1]. Among them 721 are detected in humans. The first member of the miRNA family, *lin-4*, was originally identified in *Caenorhabditis elegans* as a developmental timing regulator [2]. miRNAs play fundamental roles in the control of many biological processes such as growth, development, differentiation, proliferation and cell death [2,3]. They perform these functions by repression of their target genes. Each miRNA may target several hundred mRNAs and more than 60% of the mRNAs are predicted to have a miRNA-binding site in their 3' UTR (3' untranslated region). The huge number of miRNAs identified and evidence accumulated over the years indicate that a vast number of normal and pathological mechanisms are controlled by miRNA-mediated regulatory networks (reviewed in [4,5]).

Genomic organization, biogenesis and function

miRNAs can be intergenic, intronic or exonic. Intergenic miRNAs have either their own promoters (monocistronic) or share the same promoter (polycistronic), whereas the intronic miRNAs are present either singly or in clusters using the promoter of their host gene. miRNAs are transcribed in the nucleus by RNA polymerase II. They are 5' capped and 3' polyadenylated. The maturation of miRNAs requires two endonucleolytic cleavage steps by RNase III-like enzymes: Drosha and Dicer. Following transcription, Drosha processes the primary miRNA transcript (pri-miRNA), which can be several kilobases long, into a 60–100 nt hairpin structure named the precursor-miRNA (pre-miRNA). Pre-miRNAs are folded into mini-helical structures to be recognized by exportin-5, the nuclear export factor carrying the pre-miRNAs from the nucleus to the cytoplasm. In the cytoplasm, the pre-miRNA hairpin is cleaved at the loop end by Dicer, thereby creating a 22 nt RNA duplex comprising the mature miRNA guide strand and the miRNA* passenger strand. The mature miRNA is loaded into the RISC (RNA-induced silencing complex), whereas the passenger strand is degraded (Figure 1). The exact details of the miRNA biogenesis mechanism are still to be investigated, and much less is known about the mechanisms regulating the expression of miRNAs. Recent studies point out that not all miRNAs are created by the same mechanisms. After being loaded into the RISC complex mature miRNAs are directed to their binding sites in their target mRNAs. In broad terms, this binding leads to repression of mRNA translation by one of the following mechanisms: translational block by folding the mRNA in an inactive steric conformation, deadenylation and destabilization of the




Figure 1. Schematic representation of the process from transcription of a miRNA gene in the nucleus to mature regulatory miRNA binding to target mRNA in the cytosol

Upon binding to the target mRNA the process may be negatively regulated by different mechanisms, i.e. translational repression, mRNA destabilization, mRNA cleavage or sequestration in P-bodies.

mRNA, cleavage of the mRNA or sequestration in P-bodies (processing bodies) (reviewed in [4,6,7]).

miRNAs regulate important biological processes

For many biological functions it is very important to have the miRNA expression in balance. Developmental timing, differentiation, organogenesis, cell proliferation, apoptosis, differentiation of embryonic stem cells, limb development, synaptic development and plasticity, skin differentiation, cardiogenesis, normal immune function and regulation of insulin secretion in the pancreas are some of the biological functions where miRNAs play a crucial role (reviewed in [7]).

miRNA and disease

In the last decade it has become clear that aberrant miRNA deregulation and expression is observed in most human malignancies, although it is often not clear whether this deregulation is the cause or the effect of the disease. Some of the most investigated malignancies are cancers, dysfunctional heart conditions, metabolic diseases and viral infections. Very recently a knowledge-base on

Table 1. Overview of various miRNAs that are either down-regulated or up-regulated in human tumour tissue

AML, acute myeloid leukaemia; CLL, chronic lymphocytic leukaemia.

miRNA	Tumour tissue	Changed expression in tumours
Let-7 family	Lung, breast, prostate, colon, gastric, ovary, CLL	Down-regulated
miR-101	Prostate, liver and bladder	Down-regulated
miR-122a	Liver	Down-regulated
miR-143	Colon, breast, lung, cervix, B-cell	Down-regulated
miR-145		
miR-15a	CLL, prostate, pancreas and multiple myeloma	Down-regulated
miR-16-1		
miR-155	CLL, Burkitt's lymphoma, lung, breast, pancreas and colon	Up-regulated
miR-221	Leukaemia	Down-regulated
miR-222		
miR-29 family	CLL, AML, breast, colon and lung	Down-regulated
miR-34 family	Pancreas, colon, breast and liver	Down-regulated
miR-372	Testis	Up-regulated
miR-373		
miR-17-92 cluster	Lymphomas, breast, lung, colon, stomach and pancreas	Up-regulated
miR-106b-93-25 cluster	Gastric, colon, prostate and neuroblastoma	Up-regulated
miR-21	Glioblastoma, ALM, CLL, Burkitt's lymphoma, breast, colon, pancreas, lung, prostate, liver and stomach, cervix, head and neck cancers	Up-regulated
miR-221	CLL, thyroid, liver and glioblastoma	Up-regulated
miR-222		

the aberrant expression of miRNAs in various diseases was introduced [8]. In cancers, miRNAs can act either as oncogenes or tumour suppressors, and a multitude of papers have investigated the differential expression of miRNAs in tumour tissues and their function in cancer cells and metastatic potential (see Table 1 for an overview). Many miRNAs act as tumour suppressor genes and they are frequently silenced in cancers. However, the underlying mechanism for this is less clear. One explanation is epigenetic silencing of miRNA genes and this has now been described in various cancers for several miRNAs.

Mechanisms such as change in turnover rate or DNA copy number could be other reasons for differential expression of miRNAs which need to be further investigated [9,10].

Introduction to miRNA and epigenetics

Epigenetic phenomena such as DNA methylation of CpG islands in promoter regions of genes and histone modifications are well known to regulate gene expression. The major epigenetic changes in cancer are aberrant DNA hypermethylation of tumour suppressor genes, global genomic DNA hypomethylation and disruption of the histone modification patterns.

Like classical protein coding genes, miRNA genes are also subject to epigenetic regulation and miRNAs can also regulate various components of the epigenetic machinery. For a detailed review, see [11].

Epigenetic regulation of miRNA expression in cancer

Several miRNAs are down-regulated in cancer and act as *bona fide* tumour suppressor genes, and therefore these miRNAs are obvious candidates for epigenetic silencing. High-quality papers have been published on the impact of epigenetic regulation of miRNA genes with regard to cell proliferation, apoptosis, tumour suppressor or oncogenic effects both in cell culture systems, *in vivo* models and in various human primary tumours. The epigenetic status has also been correlated with metastatic status and with survival of cancer patients, which will be the focus of this part of the chapter. An up-to-date overview is presented in Table 2.

The concept of controlling miRNA expression by epigenetic mechanisms may be as widespread as for protein coding genes, since half of the miRNA genes are associated with CpG islands and miRNA gene methylation is detected with high frequency in normal and malignant cells [12].

A common approach to identifying epigenetically regulated miRNAs has been to treat cancer cells with inhibitors of DNA methylation (e.g. 5-azacytidine) and/or histone deacetylases [e.g. PBA (4-phenylbutyric acid) or TSA (trichostatin A)] and compare miRNA expression to that in untreated cells.

This approach was applied in the first two high-impact publications in this field from 2006, which identified a number of epigenetically regulated miRNAs in breast and bladder cancer cells [13,14].

It has turned out that epigenetic regulation of miRNA expression is a common hallmark in human cancers and that epigenetic tags are associated with metastatic status and clinically relevant endpoints, such as disease-free survival and overall survival, thereby suggesting their use as biomarkers in cancer detection, prognosis, monitoring and predicting response to treatment.

In CRC (colorectal cancer), epigenetically regulated miRNAs have been identified in both cell lines and in tumour tissues. The expression of miR-342 was found to be regulated by CpG island methylation. Interestingly,

Table 2. Epigenetically controlled miRNAs in cancer

miRNA	Epigenetic silencing mechanism	Cancer	Identified target	In vitro/ in vivo	Consequence of epigenetic silencing	Biomarker potential	Reference
miR-124a	Methylation and histone modification	ALL	CDK6	<i>In vitro and in vivo</i>	Abnormal proliferation of ALL cells	Hypermethylation associated with higher relapse rate and mortality rate	[24]
miR-124a	Methylation	Gastric		<i>In vivo</i>		Methylation of miR-124a is increased by <i>H. pylori</i> infection	[42]
miR-9	Methylation	Colorectal		<i>In vitro</i>		Hypermethylated in CRC tumours compared with normal colonic mucosa.	[19]
miR-129	(chromatin modification)					Methylation of miR-9-1 is associated with lymph node metastasis	
miR-137				<i>In vivo</i>		Hypermethylated in lung adenocarcinomas	[43]
Let-7a-3	Methylation	Colorectal		<i>In vitro</i>	Suppresses tumour phenotype		
miR-203	Methylation	Haematopoietic tumours	ABL1	<i>In vivo</i> <i>In vitro</i>	Promotes tumour cell proliferation	Methylated in human leukaemias	[44]
miR-1-1	Methylation (histone modification)	Liver	BCR-ABL1 FOXPI	<i>In vivo</i> <i>In vitro</i>	Promotes cell growth, replication potential and clonogenic survival		[45]

miR-223	Methylation (chromatin remodelling)	AML	MET HDAC4	<i>In vivo</i>	Leukaemia differentiation block	[46]
miR-124	Methylation	Hepatocellular carcinoma (HCC)	miR-124: CDK6, vimentin, SMYD3, IQGAPI	<i>In vitro</i>	Promotes HCC cell growth (124 and miR-203)	[47]
miR-203			miR-203: ABCE1	<i>In vivo</i>		
miR-375						
miR-342	Methylation of the host gene EVL	Colorectal		<i>In vitro</i>	Anti-apoptotic	Increased methylation in CRC adenocarcinomas [15]
miR-181c	Methylation	Gastric colorectal	NOTCH4	<i>In vivo</i>	Promotes cell growth	[48]
miR-9-3	Methylation	Breast	KRAS p53-related apoptotic pathway	<i>In vitro</i>	Promotes cell proliferation	[49]
miR-129-2	Histone modification Methylation	Endometrial	SOX4	<i>In vitro</i>	Promotes cell proliferation	Hypermethylated in tumours correlated with a poor overall survival [50]
miR-21	Histone modification Methylation	Ovary		<i>In vivo</i> <i>In vitro</i>		[51]

(Continued)

Table 2. (Continued)

miR-203								
miR-205								
miR-34b	Methylation	Oral	miR-137: CDK6	<i>In vitro</i>	miR-137 and miR-193a: promotes cell growth	Down-regulated through tumour-specific hypermethylation	[52]	
miR-137			miR-193a: E2F 6	<i>In vivo</i>				
miR-193a								
miR-203								
miR-107	Methylation (histone TSA treatment)	Pancreatic	CDK6	<i>In vitro</i>	Promotes cell proliferation		[53]	
miR-9-1	Methylation	Breast		<i>In vitro</i>		Hypermethylation of miR-9-1 in primary tumours	[18]	
miR-124a3				<i>In vivo</i>				
miR-148								
miR-152								
miR-663								
miR-34a	Methylation	Prostate	CDK6	<i>In vitro</i>	Anti-apoptotic/oncogenic	Methylated in primary prostate carcinomas and primary melanoma	[54]	
		Breast Lung Colon Kidney Bladder		<i>In vivo</i>				

Let-7a-3	Methylation	Pancreas Melanoma Ovarian	<i>In vivo</i>	Methylated in ovarian cancer and associated to improved survival [22]
miR-9	Methylation	CRC	<i>In vitro</i>	miR-34b/c and miR-148a: promote mobility, tumour growth and metastasis formation [55]
miR-34b/c				
miR-148a				
miR-124a	Methylation	Melanoma Head and neck Lung Breast Colon	<i>In vivo</i>	Hypermethylation in CRC tumours [16]
miR-370	Methylation	Breast Lung Leukaemia Lymphoma Neuroblastoma Sarcoma Cholangiocarcinoma	<i>In vivo</i>	Promotes cell growth [56]
		MAP3K8		

(Continued)

Table 2. (Continued)

miR-193b	Methylation	Prostate	<i>In vitro</i>	Promotes cell growth	[57]
miR-9-1/2/3	Methylation	ALL	<i>In vivo</i> <i>In vitro</i>	Hypermethylation predicts DSF and OS	[23]
miR-10b	Histone modification		<i>In vivo</i>		
miR-34b/c					
miR-124a1/2/3					
miR-132					
miR-196b					
miR-203					
miR-212					
miR-127 and others	Methylation	Prostate	<i>In vitro</i>	BCL6	Heavily methylated in both normal and tumour tissue [13]
miR-126	Histone modification	Bladder Colon Prostate	<i>In vivo</i> <i>In vitro</i>		[58]
miR-512-5p	Histone modification Intronic miRNA regulated by methylation of host gene (EGFL7) Methylation	Bladder Gastric	<i>In vivo</i> <i>In vitro</i>	MCL-1	Anti-apoptotic [59]

miR-27a/b	Histone modification	Breast	ZBTB10/RINZF	<i>In vitro</i>	[14]
miR34b/c	Histone modification	Breast	RYPB/DEDAF	<i>In vitro</i>	[17]
miR-141	Methylation	CRC		<i>In vivo</i>	Hypermethylated in 90% of tumours
miR-200c	Methylation	Gastric		<i>In vitro</i>	[60]
Various	Methylation	Breast		<i>In vitro</i>	[61]
miR-141	Histone modification	Prostate			[12]
Various	Methylation (approx. 50% of miRNA genes associated with CpG islands)	Cervix			
Various (miRNA cluster at DLK1-Gtl2 Domain)	Methylation	Colon Ovarian	Various (microarray analysis)	<i>In vitro</i>	Down-regulation of miRNAs located at DLK1-Gtl2 domain is associated with higher tumour proliferation and shorter patient survival.
		Breast Colon		<i>In vivo</i>	

methylation of miR-342 may be specific to CRC, since *in vitro* studies employing 40 non-CRC cell lines only found partial methylation in a single cell line. Analysis of tissue indicated that methylation of miR-342 may be an early event in CRC since methylation was detected in 86% of CRC adenocarcinomas and in 67% of adenomas [15]. Comparison of normal and colon cancer tissues has shown that miR-124a is hypermethylated in 75% of the tumours ($n=56$) [14]. Methylation of miR-124a was also found in tumours from the lungs (48%, $n=27$) and breast (32%, $n=22$), but not in neuroblastomas or sarcomas [16]. Analysis of primary CRC tumours ($n=111$) and adjacent normal colon ($n=17$) found that miR-34b/c was methylated in 90% of the primary CRC tissues and very limited methylation was found in the normal mucosa [17].

In primary breast cancer specimens, aberrant hypermethylation has been shown for miR-9-1, miR-124a3, miR-148, miR-152 and miR-663 in 34–86% of cases in a series of 71 primary human breast cancer specimens [18]. The miR-9-1 gene is hypermethylated in pre-invasive intraductal lesions, suggesting that hypermethylation of miR-9-1 is an early and frequent event in breast cancer development.

Two reports have associated methylation of miRNA genes with metastatic status of cancer patients.

Bandres et al. [19] identified five down-regulated miRNAs in primary CRC, which were located in the vicinity (<1000 bp) of a CpG island. Methylation status for three of these were analysed in primary CRC samples and adjacent normal tissue, and miR-9-1, miR-129-2 and miR-137 were methylated in 56% ($n=36$), 91% ($n=34$) and 100% ($n=31$) of primary CRC cases respectively. Methylation of miR-9-1 was totally absent in histological normal mucosa and methylation was more frequent in stage III and IV compared with stage I and II. Importantly, methylation status of miR-9-1 was associated with regional nodal invasion, vascular invasion and metastasis in a group of 32 patients (16 non-methylated and 20 methylated).

In a recent report, direct relation of miRNA hypermethylation and metastasis was explored [20]. Cell lines established from lymph node metastasis were treated with 5-azacytidine and the miRNA expression relative to untreated cells was investigated. These experiments identified 16 hypermethylated and up-regulated miRNAs, located in the proximity of a CpG island. Comparison with methylation status of non-cancerous tissues further reduced the number of miRNAs displaying cancer-specific CpG island hypermethylation. The selected miRs – miR-148a, miR-34b/c, and miR-9-1/2/3 – were tested *in vitro* and *in vivo* for their potential involvement in metastasis. Re-introduction of miR-34b/c and miR-148 into a metastatic carcinoma cell line, which is hypermethylated and silenced for miR-34b/c and miR-148 expression, reduced the migratory capability of the cancer cells. Likewise, experiments with nude mice showed that re-introduction of miR-34b/c and miR-148 caused reduced tumour growth and diminished metastatic potential of the metastatic carcinoma

cell line. A collection of primary tumour samples ($n=278$) from various tumour types were analysed and hypermethylation was undetectable in the corresponding normal tissue. Notably, hypermethylation of miR-34b/c, miR-148 and miR-9-3 in primary tumours was significantly associated with those tumours that were positive for metastatic cancer cells in the corresponding lymph nodes ($n=207$).

In a report focusing on ovarian cancer, eight miRNAs (miR-337, miR-368, miR-376a/b, miR-377, miR-410, miR-432, miR-495) located in the chromosome 14 miRNA cluster (*Dlk1-Gtl2* domain) were identified as potential tumour suppressor genes regulated by DNA methylation [21]. An expression signature separated late-stage ovarian cancers ($n=73$) into two distinct clusters. Patients belonging to the cluster with low expression of the eight miRNAs displayed higher tumour proliferation and had shorter 5-year survival. Analysis of other cancer types indicated that down-regulation of the chromosome 14 miRNA cluster may be an event common to many human epithelial tumours.

The *let-7a-3* gene is located in a CpG island and its methylation status was analysed in 214 malignant tumours: no correlation between disease stage and tumour grade was detected [22]. Although the disease-free survival was not associated with methylation of *let-7a-3*, the patients with low *let-7a-3* methylation ($n=138$) had significantly worse overall survival than those with high methylation ($n=67$).

Two reports from the same laboratory have analysed epigenetic regulation of miRNA expression in ALL (acute lymphoblastic leukaemia) and associated it with clinical outcome.

In ALL-derived cell lines, analysis of histone modifications around CpG islands located in the 5' UTR of miRNA genes identified 13 miRNA candidate genes for epigenetic silencing: miR-9-1/2/3, miR-10b, miR-34b/c, miR-124a1/a2/a3, miR-132, miR-196b, miR-203 and miR-212 [23]. Methylation of at least one in 13 miRNA was found in 65% ($n=353$) of the ALL human tumours and was a strong and independent negative prognostic marker for disease-free survival and overall survival.

In ALL patients, miR-124 is regulated by CpG island hypermethylation and histone modifications, and re-introduction of miR-124a severely reduced tumorigenicity of ALL cells in a xenograft mouse model [24]. The miR-124a methylation status was analysed in 353 ALL patients and hypermethylation was found in 59%; this correlated with decreased expression of miR-124a. Furthermore, hypermethylation significantly correlated with higher relapse and mortality rates, and multivariate analysis showed that miR-124a is an independent prognostic factor for both disease-free survival and overall survival.

Taken together, these results show that DNA demethylation and HDAC (histone deacetylase) inhibition can activate expression of miRNAs and further large-scale clinical investigations are clearly warranted.

miRNAs as regulators of epigenetic processes

As well as being regulated by epigenetic mechanisms, miRNAs also play a role in controlling the chromatin structure by post-transcriptional regulation of chromatin-modifying enzymes (reviewed in [11,25]). Among the predicted human miRNA target genes there are a number of genes involved in epigenetic regulation, such as the methyl CpG-binding proteins, HMTs (histone methyltransferases), chromodomain-containing proteins and HDACs [26]. This subset of miRNAs, which directly or indirectly regulate the expression levels of effectors of the epigenetic processes, have been termed 'epi-miRNAs' [11]. Aberrant regulation of miRNA expression plays an important and direct role in the aberrant epigenetic silencing of tumour suppressor genes by DNA methylation in human cancers (see Table 3).

DNA methylation patterns are laid down during development by DNMT3a and DNMT3b (where DNMT is DNA methyltransferase), whereas maintenance during replication is facilitated by DNMT1. The first direct link between a miRNA and the DNMTs was established between the miR-29 family (miR-29a/b/c) and DNMT3a and DNMT3b, and other miRNAs such as miR-148 and miR-143 have also been indicated as regulators of the methylation enzymes. In non-small cell carcinoma of the lung, miR-29 is down-regulated, whereas the DNMT3A and DNMT3B expression is increased. Re-expression of miR-29 is shown to disrupt the *de novo* DNA methylation and caused general hypomethylation, leading to expression of tumour suppressor genes that are silenced by methylation, which resulted in apoptosis in cancer cells both *in vitro* and *in vivo*. This study indicated that miR-29 regulates the DNMT3 genes in lung cancer and revealed a new mechanism whereby the miRNAs indirectly regulate the gene expression through direct regulation of epigenetic mechanisms [27]. Another group has shown that overexpression of *miR-29b* in AML (acute myeloid leukaemia) cells resulted in marked reduction of DNMT1, DNMT3A and DNMT3B at both the RNA and protein levels. They concluded that the expression of *miR-29b* promoted DNA hypomethylation not only through direct targeting of DNMT3a and DNMT3b, but also by decreasing the DNMT1 expression indirectly via down-regulation of *Sp1*, a known transactivating factor of the DNMT1 gene [28].

Furthermore, miR-143 regulates DNMT3a in CRC cells, whereas miR-148a and miR-148b represses Dnmt3b expression in mouse cells through binding to a highly conserved sequence in its coding region rather than the 3' UTR [29,30]. Benetti et al. [31] proposed a new regulatory pathway for DNA methylation involving the mammalian miR-290 cluster (miR-290, miR-291-3p, miR-291-5p, miR-292-3p, miR-292-5p, miR-293, miR-294 and miR-295) as an important regulator of Rbl2, which in turn acts as a transcriptional repressor of Dnmt3a and Dnmt3b causing hypomethylation in the genome, especially in the telomeres. The whole cluster is shown to be down-regulated in Dicer-null cells in mouse, whereas Rbl2 is increased in expression leading to repression of Dnmt3a and Dnmt3b causing DNA methylation defects [31]. However, the

Table 3. Overview of the miRNAs that regulate the enzymes playing major roles in epigenetic processes

miRNA	Epigenetic mechanism regulated	Cell type/disease	Target	Mechanism of action	Consequence	Reference
miR-29a	De novo DNA methylation	Non-small cell carcinoma of the lung	DNMT3a	Up-regulation disrupts de novo methylation	Apoptosis of cancer cells, inhibition of cancer growth	[27]
miR-29b			DNMT3b			
miR-29c						
miR-29b	Global methylation	AML	SPI	Silences DNMT1	Global hypomethylation	[28]
miR-143	DNA methylation	CRC	DNMT3a	Inversely correlated with DNMT3A	Decreased tumour cell growth and soft-agar colony formation	[29]
miR-148a	De novo DNA methylation	Testicular germ cell tumour cells	DNMT3b1	Translational repression, mRNA degradation		[30]
miR-148b						
miR-290 cluster (miR-290, miR-291-3p, miR-291-5p, miR-292-3p, miR-292-5p, miR-293, miR-294 miR-295)	De novo DNA methylation	Mouse embryonic stem cell	RBL2	Regulates Rbl2, a transcriptional repressor of Dnmt3a and Dnmt3b	Down-regulation results in increased telomere recombination, aberrant telomere elongation	[31]
	No effect	Human embryonic kidney cells	No regulatory effect on methylation in human cells	Species and cell type specific		[32]
miR-206	Histone deacetylation	Mouse skeletal muscles	HDAC4	Translational inhibition	Modifier of ALS pathogenesis	[62]

(Continued)

Table 3. (Continued)

miR-140	Histone deacetylation	Mouse cartilage cells	HDAC4	Suppression of HDAC4	Differentiation	[35]
miR-1	Histone deacetylation	Skeletal muscle tissue	HDAC4	Suppression of HDAC4		[34]
miR-1 miR-499	Histone deacetylation	Human-derived cardiomyocyte progenitor cells	HDAC4		Reduced proliferation, enhanced differentiation into cardiomyocytes	[37]
miR-449a	Histone deacetylation	Prostate cancer cells	SOX6 HDAC1	Directly targets and represses HDAC1	Cell-cycle arrest apoptosis	[38]
miR-101	Histone methylation	Prostate and bladder cancer	EZH2	Targets EZH2 which is the catalytic subunit of the Polycomb repressive complex 2 responsible for histone H3 lys 27 trimethylation, a mark of epigenetic repression	Inhibition of cancer formation	[39,40]
miR-2861	Histone deacetylation	Primary mouse osteoblasts	HDAC5	Repression of histone deacetylase 5	Promotes osteoblast differentiation	[63]

regulatory effect of the miR-290 cluster on methylation cannot be shown in DICER-knockdown human embryonic kidney cells. This indicates that the miR-290 clusters' effect on DNMTs could be cell-type- or species-specific [32]. Recently, a completely new mechanism was suggested for regulation of gene expression by miRNAs in moss. Khraiwesh et al. propose that initiation of epigenetic silencing by DNA methylation is regulated according to the ratio of the miRNA and its target mRNA [33].

miRNAs also regulate the expression of HDACs and HMTs. HDAC4 is shown to be a direct target of miR-1 and miR-140 [34,35]. A new miRNA HDAC4 regulatory mechanism has been revealed in ALS (amyotrophic lateral sclerosis) which is the most common adult motor neuron disease. miR-206 is shown to delay the progression of ALS, and HDAC4 is both computationally and experimentally shown to be a target of miR-206. Interestingly, in miR-206^{-/-} animals the HDAC4 protein expression is increased in skeletal muscles, whereas *Hdac4* mRNA levels were not changed. This indicated that miR-206 acts upon *Hdac4* by translational inhibition rather than at the transcription level [36]. miR-1 and miR-499 are indicated in differentiation of cardiomyocytes, possibly by repression of HDAC4 and SOX6 genes [37].

miR-449a targets HDAC1, which is up-regulated in many cancer forms. miR-449a is down-regulated in cancer, but introduction to prostate cancer cells resulted in cell-cycle arrest and apoptosis [38]. Similarly re-expression of miR-101 in cancer models also resulted in inhibition of cancer formation. miR-101 targets EZH2, the catalytic subunit of the Polycomb repressive complex 2 responsible for histone H3 Lys²⁷ trimethylation, a mark of epigenetic repression, and can alter the chromatin structure globally [39,40]. Li et al. [41] identified a new miRNA (miR-2861) in primary mouse osteoblasts that promotes osteoblast differentiation by repressing HDAC5 expression at the post-transcriptional level.

Conclusions

Recently, the molecular mechanisms of epigenetic regulation of miRNA expression and miRNA-mediated control of the epigenetic machinery have attracted much attention, especially in cancer research. By now it is apparent that some miRNA genes are regulated by DNA CpG island hypermethylation and chromatin modifications. Interestingly, these epigenetic marks are potential biomarkers since significant correlations with survival of cancer patients have been found. Likewise, it is also clear that miRNAs regulate various components of the epigenetic machinery and thereby contribute to the regulation of the expression of other genes.

It is essential to explore in more detail this new layer of complexity in gene regulation to improve our understanding of the regulation of the human genome. Importantly, these new insights on the intertwined relationship between miRNA and epigenetics are likely to lead to novel revolutionary anti-cancer therapeutic approaches. Such approaches may be targeting

components of the epigenetic network to cause re-expression of miRNA tumour suppressor genes or directly targeting mature miRNAs or re-expressing miRNAs in order to directly affect target genes and regulate epigenetic feedback loops.

Summary

- *miRNAs are small non-protein coding molecules that regulate more than 30% of the protein coding genes.*
- *miRNAs play an important role in many biological processes such as differentiation, organ development and proliferation.*
- *In cancer and some other diseases such as diabetes, neurological and cardiac diseases, a perturbed miRNA expression is found in the relevant tissues.*
- *Some miRNAs are regulated by epigenetic mechanisms, especially by methylation.*
- *Methylation status of some miRNA genes correlates with survival of cancer patients.*
- *miRNAs may regulate the epigenetic machinery directly or indirectly by targeting enzymes such as DNMTs or HDACs.*

The Wilhelm Johannsen Centre for Functional Genome Research is established by the Danish National Research Foundation.

References

1. Griffiths-Jones, S., Grocock, R.J., van Dongen, S., Bateman, A. and Enright, A.J. (2006) miRBase: microRNA sequences, targets and gene nomenclature. *Nucleic Acids Res.* **34**, D140–D144
2. Lee, R.C., Feinbaum, R.L. and Ambros, V. (1993) The *C. elegans* heterochronic gene *lin-4* encodes small RNAs with antisense complementarity to *lin-14*. *Cell* **75**, 843–854
3. Bartel, D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* **116**, 281–297
4. Davis, B.N. and Hata, A. (2009) Regulation of microRNA biogenesis: a miRiad of mechanisms. *Cell Commun. Signal.* **7**, 18
5. Taft, R.J., Pang, K.C., Mercer, T.R., Dinger, M. and Mattick, J.S. (2010) Non-coding RNAs: regulators of disease. *J. Pathol.* **220**, 126–139
6. Olena, A.F. and Patton, J.G. (2010) Genomic organization of microRNAs. *J. Cell Physiol.* **222**, 540–545
7. Friedman, J.M. and Jones, P.A. (2009) MicroRNAs: critical mediators of differentiation, development and disease. *Swiss Med Wkly* **139**, 466–472
8. Ruepp, A., Kowarsch, A., Schmidl, D., Bruggenthin, F., Brauner, B., Dunger, I., Fobo, G., Frishman, G., Montrone, C. and Theis, F.J. (2010) PhenomiR: a knowledgebase for microRNA expression in diseases and biological processes. *Genome Biol.* **11**, R6
9. Kai, Z.S. and Pasquinelli, A.E. (2010) MicroRNA assassins: factors that regulate the disappearance of miRNAs. *Nat. Struct. Mol. Biol.* **17**, 5–10
10. Mi, S., Li, Z., Chen, P., He, C., Cao, D., Elkahloun, A., Lu, J., Pelloso, L.A., Wunderlich, M., Huang, H. et al. (2010) Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 3710–3715

11. Valeri, N., Vannini, I., Fanini, F., Calore, F., Adair, B. and Fabbri, M. (2009) Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation. *Mamm. Genome* **20**, 573–580
12. Weber, B., Stresmann, C., Brueckner, B. and Lyko, F. (2007) Methylation of human microRNA genes in normal and neoplastic cells. *Cell Cycle* **6**, 1001–1005
13. Saito, Y., Liang, G., Egger, G., Friedman, J.M., Chuang, J.C., Coetzee, G.A. and Jones, P.A. (2006) Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. *Cancer Cell* **9**, 435–443
14. Scott, G.K., Mattie, M.D., Berger, C.E., Benz, S.C. and Benz, C.C. (2006) Rapid alteration of microRNA levels by histone deacetylase inhibition. *Cancer Res.* **66**, 1277–1281
15. Grady, W.M., Parkin, R.K., Mitchell, P.S., Lee, J.H., Kim, Y.H., Tsuchiya, K.D., Washington, M.K., Paraskeva, C., Willson, J.K., Kaz, A.M. et al. (2008) Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. *Oncogene* **27**, 3880–3888
16. Lujambio, A., Ropero, S., Ballestar, E., Fraga, M.F., Cerrato, C., Setién, F., Casado, S., Suarez-Gauthier, A., Sanchez-Cespedes, M., Git, A. et al. (2007) Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. *Cancer Res.* **67**, 1424–1429
17. Toyota, M., Suzuki, H., Sasaki, Y., Maruyama, R., Imai, K., Shinomura, Y. and Tokino, T. (2008) Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. *Cancer Res.* **68**, 4123–4132
18. Lehmann, U., Hasemeier, B., Christgen, M., Müller, M., Römermann, D., Länger, F. and Kreipe, H. (2008) Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. *J. Pathol.* **214**, 17–24
19. Bandres, E., Agirre, X., Bitarte, N., Ramirez, N., Zarate, R., Roman-Gomez, J., Prosper, F. and Garcia-Foncillas, J. (2009) Epigenetic regulation of microRNA expression in colorectal cancer. *Int. J. Cancer* **125**, 2737–2743
20. Lujambio, A., Calin, G.A., Villanueva, A., Ropero, S., Sánchez-Céspedes, M., Blanco, D., Montuenga, L.M., Rossi, S., Nicoloso, M.S., Faller, W.J. et al. (2008) microRNA DNA methylation signature for human cancer metastasis. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 13556–13561
21. Zhang, L., Volinia, S., Bonome, T., Calin, G.A., Greshock, J., Yang, N., Liu, C.G., Giannakakis, A., Alexiou, P., Hasegawa, K. et al. (2008) Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 7004–7009
22. Lu, L., Katsaros, D., de la Longrais, I.A., Sochirca, O. and Yu, H. (2007) Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. *Cancer Res.* **67**, 10117–10122
23. Roman-Gomez, J., Agirre, X., Jiménez-Velasco, A., Arqueros, V., Vilas-Zornoza, A., Rodriguez-Otero, P., Martin-Subero, I., Garate, L., Cordeu, L., San José-Eneriz, E. et al. (2009) Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. *J. Clin. Oncol.* **27**, 1316–1322
24. Agirre, X., Vilas-Zornoza, A., Jiménez-Velasco, A., Martin-Subero, J.I., Cordeu, L., Gárate, L., San José-Eneriz, E., Abizanda, G., Rodríguez-Otero, P., Fortes, P. et al. (2009) Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. *Cancer Res.* **69**, 4443–4453
25. Davalos, V. and Esteller, M. (2010) MicroRNAs and cancer epigenetics: a macrorevolution. *Curr. Opin. Oncol.* **22**, 35–45
26. Guil, S. and Esteller, M. (2009) DNA methylomes, histone codes and miRNAs: tying it all together. *Int. J. Biochem. Cell Biol.* **41**, 87–95
27. Fabbri, M., Garzon, R., Cimmino, A., Liu, Z., Zanesi, N., Callegari, E., Liu, S., Alder, H., Costinean, S., Fernandez-Cymering, C. et al. (2007) MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 15805–15810
28. Garzon, R., Liu, S., Fabbri, M., Liu, Z., Heaphy, C.E., Callegari, E., Schwind, S., Pang, J., Yu, J., Muthusamy, N. et al. (2009) MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. *Blood* **113**, 6411–6418
29. Ng, E.K., Tsang, W.P., Ng, S.S., Jin, H.C., Yu, J., Li, J., Röcken, C., Ebert, M.P., Kwok, T.T. and Sung, J.J. (2009) MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. *Br. J. Cancer* **101**, 699–706

30. Duursma, A.M., Kedde, M., Schrier, M., le Sage, C. and Agami, R. (2008) miR-148 targets human DNMT3b protein coding region. *RNA* **14**, 872–877
31. Benetti, R., Gonzalo, S., Jaco, I., Muñoz, P., Gonzalez, S., Schoeftner, S., Murchison, E., Andl, T., Chen, T., Klatt, P. et al. (2008) A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. *Nat. Struct. Mol. Biol.* **15**, 268–279
32. Sinkkonen, L., Hugenschmidt, T., Berninger, P., Gaidatzis, D., Mohn, F., Artus-Revel, C.G., Zavolan, M., Svoboda, P. and Filipowicz, W. (2008) MicroRNAs control de novo DNA methylation through regulation of transcriptional repressors in mouse embryonic stem cells. *Nat. Struct. Mol. Biol.* **15**, 259–267
33. Khraiwesh, B., Arif, M.A., Seumel, G.I., Ossowski, S., Weigel, D., Reski, R. and Frank, W. (2010) Transcriptional control of gene expression by microRNAs. *Cell* **140**, 111–122
34. Chen, J.F., Mandel, E.M., Thomson, J.M., Wu, Q., Callis, T.E., Hammond, S.M., Conlon, F.L. and Wang, D.Z. (2006) The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. *Nat. Genet.* **38**, 228–233
35. Tuddenham, L., Wheeler, G., Ntounia-Fousara, S., Waters, J., Hajhosseini, M.K., Clark, I. and Dalmay, T. (2006) The cartilage specific microRNA-140 targets histone deacetylase 4 in mouse cells. *FEBS Lett.* **580**, 4214–4217
36. Williams, A.H., Valdez, G., Moresi, V., Qi, X., McAnally, J., Elliott, J.L., Bassel-Duby, R., Sanes, J.R. and Olson, E.N. (2009) MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. *Science* **326**, 1549–1554
37. Sluijter, J.P., van Mil, A., van Vliet, P., Metz, C.H., Liu, J., Doevendans, P.A. and Goumans, M.J. (2010) MicroRNA-1 and -499 regulate differentiation and proliferation in human-derived cardiomyocyte progenitor cells. *Arterioscler. Thromb. Vasc. Biol.* **30**, 859–868
38. Noonan, E.J., Place, R.F., Pookot, D., Basak, S., Whitson, J.M., Hirata, H., Giardina, C. and Dahiya, R. (2009) miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. *Oncogene* **28**, 1714–1724
39. Varambally, S., Cao, Q., Mani, R.S., Shankar, S., Wang, X., Ateeq, B., Laxman, B., Cao, X., Jing, X., Ramnarayanan, K. et al. (2008) Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. *Science* **322**, 1695–1699
40. Friedman, J.M., Liang, G., Liu, C.C., Wolff, E.M., Tsai, Y.C., Ye, W., Zhou, X. and Jones, P.A. (2009) The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. *Cancer Res.* **69**, 2623–2629
41. Li, H., Xie, H., Liu, W., Hu, R., Huang, B., Tan, Y.F., Xu, K., Sheng, Z.F., Zhou, H.D., Wu, X.P. and Luo, X.H. (2009) A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. *J. Clin. Invest.* **119**, 3666–3677
42. Ando, T., Yoshida, T., Enomoto, S., Asada, K., Tatematsu, M., Ichinose, M., Sugiyama, T. and Ushijima, T. (2009) DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. *Int. J. Cancer* **124**, 2367–2374
43. Brueckner, B., Stresemann, C., Kuner, R., Mund, C., Musch, T., Meister, M., Sülthmann, H. and Lyko, F. (2007) The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. *Cancer Res.* **67**, 1419–1423
44. Bueno, M.J., Pérez de Castro, I., Gómez de Cedrón, M., Santos, J., Calin, G.A., Cigudosa, J.C., Croce, C.M., Fernández-Piqueras, J. and Malumbres, M. (2008) Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. *Cancer Cell* **13**, 496–506
45. Datta, J., Kutay, H., Nasser, M.W., Nuovo, G.J., Wang, B., Majumder, S., Liu, C.G., Volinia, S., Croce, C.M., Schmittgen, T.D., Ghoshal, K. and Jacob, S.T. (2008) Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. *Cancer Res.* **68**, 5049–5058
46. Fazi, F., Racanicchi, S., Zardo, G., Starnes, L.M., Mancini, M., Travaglini, L., Diverio, D., Ammatuna, E., Cimino, G., Lo-Coco, F. et al. (2007) Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. *Cancer Cell.* **12**, 457–466

47. Furuta, M., Kozaki, K.I., Tanaka, S., Arii, S., Imoto, I. and Inazawa, J. (2010) miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. *Carcinogenesis* **31**, 766–776
48. Hashimoto, Y., Akiyama, Y., Otsubo, T., Shimada, S. and Yuasa, Y. (2010) Involvement of epigenetically silenced microRNA-181c in gastric carcinogenesis. *Carcinogenesis* **31**, 777–784
49. Hsu, P.Y., Deatherage, D.E., Rodriguez, B.A., Liyanarachchi, S., Weng, Y.I., Zuo, T., Liu, J., Cheng, A.S. and Huang, T.H. (2009) Xenoestrogen-induced epigenetic repression of microRNA-9-3 in breast epithelial cells. *Cancer Res.* **69**, 5936–5945
50. Huang, Y.W., Liu, J.C., Deatherage, D.E., Luo, J., Mutch, D.G., Goodfellow, P.J., Miller, D.S. and Huang, T.H. (2009) Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. *Cancer Res.* **69**, 9038–9046
51. Iorio, M.V., Visone, R., Di Leva, G., Donati, V., Petrocca, F., Casalini, P., Taccioli, C., Volinia, S., Liu, C.G., Alder, H. et al. (2007) MicroRNA signatures in human ovarian cancer. *Cancer Res.* **67**, 8699–8707
52. Kozaki, K., Imoto, I., Mogi, S., Omura, K. and Inazawa, J. (2008) Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. *Cancer Res.* **68**, 2094–2105
53. Lee, K.H., Lotterman, C., Karikari, C., Omura, N., Feldmann, G., Habbe, N., Goggins, M.G., Mendell, J.T. and Maitra, A. (2009) Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. *Pancreatology* **9**, 293–301
54. Lodygin, D., Tarasov, V., Epanchintsev, A., Berking, C., Knyazeva, T., Körner, H., Knyazev, P., Diebold, J. and Hermeking, H. (2008) Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. *Cell Cycle*. **7**, 2591–2600
55. Lujambio, A., Calin, G.A., Villanueva, A., Ropero, S., Sánchez-Céspedes, M., Blanco, D., Montuenga, L.M., Rossi, S., Nicoloso, M.S., Faller, W.J. et al. (2008) A microRNA DNA methylation signature for human cancer metastasis. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 13556–13561
56. Meng, F., Wehbe-Janek, H., Henson, R., Smith, H. and Patel, T. (2008) Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. *Oncogene* **27**, 378–386
57. Rauhala, H.E., Jalava, S.E., Isotalo, J., Bracken, H., Lehmusvaara, S., Tammela, T.L., Oja, H. and Visakorpi, T. (2010) miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. *Int. J. Cancer*, in press
58. Saito, Y., Friedman, J.M., Chihara, Y., Egger, G., Chuang, J.C. and Liang, G. (2009) Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. *Biochem. Biophys. Res. Commun.* **379**, 726–731
59. Saito, Y., Suzuki, H., Tsugawa, H., Nakagawa, I., Matsuzaki, J., Kanai, Y. and Hibi, T. (2009) Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells. *Oncogene* **28**, 2738–2744
60. Tsai, K.W., Kao, H.W., Chen, H.C., Chen, S.J. and Lin, W.C. (2009) Epigenetic control of the expression of a primate-specific microRNA cluster in human cancer cells. *Epigenetics* **4**, 587–592
61. Vrba, L., Jensen, T.J., Garbe, J.C., Heimark, R.L., Cress, A.E., Dickinson, S., Stampfer, M.R. and Futscher, B.W. (2010) Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. *PLoS One* **5**, e8697
62. Williams, A.H., Valdez, G., Moresi, V., Qi, X., McAnally, J., Elliott, J.L., Bassel-Duby, R., Sanes, J.R. and Olson, E.N. (2009) MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. *Science* **326**, 1549–1554
63. Li, H., Xie, H., Liu, W., Hu, R., Huang, B., Tan, Y.F., Xu, K., Sheng, Z.F., Zhou, H.D., Wu, X. P., Luo, X.H. (2009) A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. *J. Clin. Invest.* **119**, 3666–3677

